• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Incyte Corporation - Common Stock (NQ:INCY)

    103.09 +2.45 (+2.43%)
    Streaming Delayed Price Updated: 12:18 PM EDT, Jun 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 610,243
    Open 102.16
    Bid (Size) 102.94 (100)
    Ask (Size) 103.10 (100)
    Prev. Close 100.64
    Today's Range 101.51 - 103.70
    52wk Range 66.74 - 112.29
    Shares Outstanding 222,430,635
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles ↗
    Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
    From Incyte
    Via Business Wire

    Performance

    YTD
    +1.6%
    +1.6%
    1 Month
    +2.8%
    +2.8%
    3 Month
    +6.2%
    +6.2%
    6 Month
    +6.6%
    +6.6%
    1 Year
    +47.5%
    +47.5%

    More News

    Read More
    Incyte Corp (NASDAQ:INCY) Screens as a Deep Value Opportunity with Strong Profitability ↗
    Via Chartmill
    News headline image
    Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
    From Mirum Pharmaceuticals, Inc. and Incyte
    Via Business Wire
    INCYTE CORP (NASDAQ:INCY) Shows Rare Alignment of High Growth Momentum and Technical Breakout Setup ↗
    Via Chartmill
    Incyte (NASDAQ:INCY) Beats Q1 Estimates and Unveils Robust Pipeline Catalysts ↗
    Via Chartmill
    Wednesday's session: top gainers and losers in the S&P500 index ↗
    Via Chartmill
    These S&P500 stocks are moving in today's session ↗
    Via Chartmill
    News headline image
    Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
    From Incyte
    Via Business Wire
    News headline image
    3 Profitable Stocks for Long-Term Investors
    Via StockStory
    News headline image
    Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
    From Incyte
    Via Business Wire
    News headline image
    Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out ↗
    Via MarketBeat
    News headline image
    Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
    From Genesis Molecular AI and Incyte
    Via Business Wire
    News headline image
    Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development
    From Incyte and Edison Scientific
    Via Business Wire
    News headline image
    Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build ↗
    Via MarketBeat
    News headline image
    Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
    From Incyte
    Via Business Wire
    News headline image
    2 Cash-Heavy Stocks with Solid Fundamentals and 1 We Ignore
    Via StockStory
    News headline image
    Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Incyte Corporation
    Via Business Wire
    News headline image
    Incyte’s Q1 Earnings Call: Our Top 5 Analyst Questions
    Via StockStory
    Topics Earnings
    News headline image
    Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
    From Incyte
    Via Business Wire
    News headline image
    Incyte to Present at Upcoming Investor Conferences
    From Incyte
    Via Business Wire
    News headline image
    INCY Q1 Deep Dive: Pipeline Advances Offset Cautious Full-Year Guidance
    Via StockStory
    News headline image
    Incyte (INCY) Q1 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Incyte (INCY) Q2 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Incyte (NASDAQ:INCY) Exceeds Q1 CY2026 Expectations
    Via StockStory

    Frequently Asked Questions

    Is Incyte Corporation - Common Stock publicly traded?
    Yes, Incyte Corporation - Common Stock is publicly traded.
    What exchange does Incyte Corporation - Common Stock trade on?
    Incyte Corporation - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Incyte Corporation - Common Stock?
    The ticker symbol for Incyte Corporation - Common Stock is INCY on the Nasdaq Stock Market
    What is the current price of Incyte Corporation - Common Stock?
    The current price of Incyte Corporation - Common Stock is 103.09
    When was Incyte Corporation - Common Stock last traded?
    The last trade of Incyte Corporation - Common Stock was at 06/09/26 12:18 PM ET
    What is the market capitalization of Incyte Corporation - Common Stock?
    The market capitalization of Incyte Corporation - Common Stock is 22.93B
    How many shares of Incyte Corporation - Common Stock are outstanding?
    Incyte Corporation - Common Stock has 23B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.